IND submission is a major milestone in the life of your drug. We can provide all supporting analytical data to help ensure a smooth application process.
We have the expertise, flexibility, and resources to provide a full range of pharmaceutical API custom development services at every stage of the lifecycle.
We can provide lab-, kilo- and pilot-scale manufacturing for preclinical studies and all phases of clinical trials, supplying milligram to kilogram quantities.
Cambrex brings more than 40 years of generic API manufacturing experience to its pharmaceutical partners. From our sites in Italy, Sweden, and the USA, we are a leading global supplier of generic APIs.
Drug substance tech transfer sounds so simple on the surface, but it’s a complex activity carrying a number of technical, regulatory, and quality risks.
At Snapdragon Chemistry, now part of Cambrex, our chemists specialize in creating custom solutions and technologies to take on your toughest process development and production challenges. This includes expertise in designing and building reactors that enable seamless technology transfer as a process scales up for commercial manufacturing.
At Cambrex, we provide a range of technologies equipped to solve your API manufacturing challenges, and we are flexible enough to handle the most complex molecules.
If you’re looking to outsource drug product development to a CDMO, you need a collaborative partner who will engage you deeply to understand the unique needs of your project.
From pre-formulation to commercial manufacturing and packaging, you can trust Cambrex to deliver your complex dosage forms with the perfect combination of technology, expertise, and collaboration.
At Cambrex, we offer a tried and trusted approach to technology transfer, for scale-up or when transitioning to a different facility.
We are equipped to take on projects at any size or scale, offering established pediatric formulation and development expertise and to-scale manufacturing capabilities.
Biopharma companies at all stages of development, rely on our expertise and broad capabilities to produce the clinical trial supply of drug products they need, when they need them.
We can support you, at any size or stage, with a range of primary and secondary packaging solutions.
You can rely on our extensive portfolio of analytical development solutions and testing services to rapidly advance your molecule for the greatest chance of success.
Cambrex offers a comprehensive suite of testing services for complex biopharmaceuticals including standalone analytical R&D, method validation, release testing, ICH stability, and routine QC testing.
We’re solid state chemistry experts who can deliver timely, phase-appropriate solutions to optimize the physical stability of your API, develop a more bioavailable formulation or overcome other challenges.
Cambrex’s experienced analysts are well-equipped to ensure microbial testing is of the highest quality for our customers and delivered with a quick and reliable turnaround.
Cambrex and Q1 Scientific’s stability storage and sample management capabilities provide a variety of pharmaceutical storage conditions, with walk-in and reach-in chambers that meet all ICH Q1A requirements.
Cambrex is here to support you in early-phase development. Our development experts apply their ingenuity and skill to address your unique challenges.
Our teams of creative problem-solvers work closely with you to accelerate drug development timelines, optimize processes, and meet regulatory requirements.
We understand that the commercial phase of drug development can be challenging, especially when it comes to manufacturing at scale and meeting changing market demands.
Cambrex is a leading global supplier of more than 70 generic APIs, as well as intermediates and derivatives.
02.02.2015
East Rutherford, NJ – Cambrex Corporation (NYSE: CBM, “Cambrex”) announced today that Samantha M. Hanley has been promoted to the position of Vice President, General Counsel and Secretary, reporting to Cambrex President & CEO, Steven M. Klosk. She succeeds William M. Haskel, who has decided to seek other opportunities outside of Cambrex. Mr. Haskel will remain with Cambrex through the end of February to ensure a smooth transition.
“Bill has been with Cambrex since June of 2011. In those three and a half years of service, the Company has enjoyed tremendous success and the Legal Department has strengthened significantly. I am grateful for his partnership and counsel,” said Mr. Klosk.
As General Counsel, Ms. Hanley will lead Cambrex’s legal function, overseeing commercial transactions, intellectual property, regulatory compliance, environmental, litigation, employment, corporate governance, SEC compliance, mergers and acquisitions and other legal matters.
“Samantha has over 12 years of broad international legal and corporate management experience. Her understanding of chemistry and experience in intellectual property and commercial contracts has served the Company well and has added tremendous value. In her new position as General Counsel, Samantha will have a key role as part of our management team to help guide our growth initiatives,” said Mr. Klosk.
Ms. Hanley formerly held the position of Assistant General Counsel and Assistant Secretary at Cambrex. Previously, Ms. Hanley worked at Alpharma Pharmaceuticals as Director of Intellectual Property and was an Associate with Lerner, David, Littenberg, Krumholtz & Mentlik, LLP, an intellectual property law firm.
Ms. Hanley obtained her BA in Chemistry from Emory University in Atlanta, Georgia and received her JD from Brooklyn Law School in Brooklyn, New York.